Mark your calendar for October 2-3, 2013 and join us at the Blackwell Inn on the campus of The Ohio State University for The 2013 Johanna and Ralph DeStefano Personalized Health Care Conference. Click here to register.
Playback the 2012 Personalized Health Care Conference
Follow me on TwitterMy Tweets
Tag Tweets With #P4HealthP4 Health Care is 13 of your 140 characters. Save room by tagging your tweets with #P4Health
Category Archives: P4 Medicine Update 4/4/11
Clay Marsh, MD, discusses elements necessary to advance predictive, preventive, personalized and participatory medicine – P4 Medicine – which will tranform healthcare delivery from its current reactive state to a more proactive mode (P4). View Marsh’s presentation in its entirety.
Genetic testing of participating university students was part of a special class that was conducted at the Stanford University School of Medicine last summer. The genetic pathology test was voluntary for the 54 students who participated in the eight-week course that was designed by a student.
The genotyping happened as part of the class, titled “Genetics-210, Genomics and Personalized Medicine.” It was intended to help medical students learn how to interpret genetic tests, and also to help them gain an understanding of ho learning the results of such tests could affect future patients.
The genome of the highly aggressive blood cancer multiple myeloma has been mapped by a team of North American scientists, who say their achievement will improve understanding of what causes the disease and may lead to new treatments.
“For the first time, we are able to see on a molecular basis what might be causing this malignancy,” Dr. David S. Siegel, chief of the multiple myeloma division at the John Theurer Cancer Center at Hackensack University Medical Center in New Jersey, said in a news release from the center.
“We have developed the most comprehensive molecular picture of myeloma to date, which will provide a public resource of genomic information for this disease,” Siegel said. “This is a large step forward in personalized medicine for the treatment of multiple myeloma. My hope is that this will allow us to develop more targeted, effective therapies.” Read more…
What if you could know what diseases were in your future by spitting into a tube?
Researchers are mapping out an individual’s genetic predisposition to a number of diseases and health concerns, and it all starts with your spit.
“You watch a lot of these crime shows and they just swab a DNA sample from your saliva. We thought they could … take it from our coffee cup, you know, and analyze our lipstick,” Snapp said.
“They come in, learn the information, we hand out the spit tube, everybody spits together. We get their sample, send it off to the lab. Eight weeks later, they get their result,” said Amy Sturm, a genetic counselor at The Ohio State University.
“We all have genetic risk factors. It’s a part of human life. But this could maybe unlock, you know, what you have to look forward to in the future and most of these are completely modifiable conditions,” Sturm said. Click here to view news story. Read more…
Stanford University researchers have developed a non-invasive, sequencing-based strategy for gauging rejection in organ transplant recipients.
In a study appearing online last night in the Proceedings of the National Academy of Sciences, the team reported that levels of cell-free donor DNA jump in blood samples from transplant recipients experiencing rejection compared to those who aren’t. From there, the researchers came up with a “genome transplant dynamics” strategy to test for transplant rejection by tracking donor DNA via genotyping and high-throughput sequencing — an approach they validated in a handful of heart transplant patients.
“Because transplanted organs have genomes that are distinct from the recipient’s genome, we used high-throughput shotgun sequencing to develop a universal non-invasive approach to monitoring organ health,” co-corresponding author Stephen Quake, a bioengineering researcher at Stanford, and co-authors wrote. “Our results demonstrate that cell-free DNA can be used to detect an organ-specific signature that correlates with rejection, and this measurement can be made on any combination of donor and recipient.”
Individuals receiving heart transplants are typically monitored for rejection via endomyocardial biopsies that require nipping off small samples of transplanted heart tissue. Individuals deemed at risk of rejection are then treated with anti-rejection drugs. But, researchers explained, such biopsies are expensive, invasive, and sometimes have serious side effects. They argue that a non-invasive, blood-based alternative would not only spare patients the discomfort of biopsies but might also curb unnecessary treatment. Read more…